For 2010 fourth quarter, analysts polled by Bloomberg expect the company to report a loss of 18 cents per share, against a loss of 19 cents reported in the quarter-ago period. For full year 2010, the company is seen reporting a loss per share of 68 cents and 59 cents for 2011.
The stock will likely provide an upside of 156% over the next 12 months with a consensus target price of $6.5, according to analysts polled by Bloomberg. Conversely, Celgene (CELG), Genzyme (GENZ), Osiris Therapeutics (OSIR), Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX) are likely to return around 31%, 4%, -15%, -34% and -19%, respectively.
All the four analysts covering the stock recommend buying.